Search

Author/Creator Attar, Eyal C

1. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Issue 4 (April 2020)

Authors:
Stein, Eytan M; Fathi, Amir T; DiNardo, Courtney D; Pollyea, Daniel A; Roboz, Gail J; Collins, Robert; Sekeres, Mikkael A; Stone, Richard M; Attar, Eyal C; Frattini, Mark G; Tosolini, Alessandra; Xu, Qiang; See, Wendy L; MacBeth, Kyle J; de Botton, Stéphane; Tallman, Martin S; Kantarjian, Hagop M
Journal:
Lancet
Issue:
Volume 7:Issue 4(2020)
Page Start:
e309
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Issue 4 (April 2023)

Authors:
Garcia-Manero, Guillermo; Goldberg, Aaron D; Winer, Eric S; Altman, Jessica K; Fathi, Amir T; Odenike, Olatoyosi; Roboz, Gail J; Sweet, Kendra; Miller, Crystal; Wennborg, Anders; Hickman, Denice K; Kanagal-Shamanna, Rashmi; Kantarjian, Hagop; Lancet, Jeffrey; Komrokji, Rami; Attar, Eyal C; Sallma...
Journal:
Lancet
Issue:
Volume 10:Issue 4(2023)
Page Start:
e272
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search